


CLAIMS


What is claimed is:




1. A compound having the formula (I):




wherein Z is N or N^+-O^- ; and R is hydrogen, $(\text{C}_1\text{-}\text{C}_{20})\text{alkyl}$, $(\text{C}_2\text{-}\text{C}_{20})\text{heteroalkyl}$, heteroaryl, aryl, heteroaryl($\text{C}_1\text{-}\text{C}_6$)alkyl, heteroaryl($\text{C}_2\text{-}\text{C}_6$)heteroalkyl, aryl($\text{C}_1\text{-}\text{C}_6$)alkyl or aryl($\text{C}_2\text{-}\text{C}_6$)heteroalkyl; with the proviso that when Z is N, R is not $(\text{C}_1\text{-}\text{C}_2)\text{alkyl}$, $(\text{C}_2)\text{heteroalkyl}$ or aryl($\text{C}_1\text{-}\text{C}_3$)alkyl.

2. The compound of Claim 1 wherein Z is N.
3. The compound of Claim 1 wherein Z is N^+-O^- .
4. The compound of Claim 1 wherein R is hydrogen.
5. The compound of Claim 1 wherein R is a saccharide or a saccharide derivative.
6. The compound of Claim 1 wherein R is glucuronide.
7. The compound of Claim 1 selected from the group consisting of:







and




8. The compound of Claim 7 that is



9. A pharmaceutical composition comprising the compound of Claim 1 or 7 and a pharmaceutically acceptable carrier.
10. A method of treating an CXCR3-mediated condition in a subject, said method comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.
11. A method in accordance with Claim 10, wherein said CXCR3-mediated condition is selected from the group consisting of neurodegenerative diseases, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, atherosclerosis, encephalitis, meningitis, hepatitis, nephritis, sepsis, sarcoidosis, psoriasis, eczema, uticaria, type I diabetes, asthma, conjunctivitis, otitis, allergic rhinitis, chronic obstructive pulmonary disease, sinusitis, dermatitis, inflammatory bowel disease, Behcet's syndrome, gout, cancer, viral infections, bacterial infections, organ transplant conditions and skin transplant conditions.
12. A method of treating an CXCR3-mediated condition in a subject, said method comprising administering to the subject an amount of a parent compound according to formula (II):



- that provides the subject a therapeutically effective amount of the compound of Claim 1.
13. The method of Claim 12 wherein the parent compound according to formula (II) provides the subject a therapeutically effective amount of



14. A method in accordance with Claim 13, wherein said CXCR3-mediated condition is selected from the group consisting of neurodegenerative diseases, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, atherosclerosis, encephalitis, meningitis, hepatitis, nephritis, sepsis, sarcoidosis, psoriasis, eczema, urticaria, type I diabetes, asthma, conjunctivitis, otitis, allergic rhinitis, chronic obstructive pulmonary disease, sinusitis, dermatitis, inflammatory bowel disease, Behcet's syndrome, gout, cancer, viral infections, bacterial infections, organ transplant conditions and skin transplant conditions.

15. A method in accordance with Claim 13, wherein said CXCR3-mediated condition is psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, asthma or an organ transplant condition.

16. The method of Claim 15 wherein CXCR3-mediated condition is psoriasis.

17. The method of Claim 15 wherein said CXCR3-mediated condition is inflammatory bowel disease.

18. The method of Claim 17 wherein said inflammatory bowel disease is ulcerative colitis or Crohn's disease.

19. The method of Claim 15 wherein CXCR3-mediated condition is multiple sclerosis, rheumatoid arthritis or an organ transplant condition.

20. A method in accordance with Claim 13, wherein said subject is a human.


21. A method in accordance with Claim 13 wherein said compound modulates CXCR3.

22. A method in accordance with Claim 21 wherein said compound is a CXCR3 antagonist.

23. A method of treating or preventing a condition in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of the

compound of Claim 1, wherein said condition is selected from the group consisting of neurodegenerative diseases, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, atherosclerosis, encephalitis, meningitis, hepatitis, nephritis, sepsis, sarcoidosis, psoriasis, eczema, uticaria, type I diabetes, asthma, conjunctivitis, otitis, allergic rhinitis, chronic obstructive pulmonary disease, sinusitis, dermatitis, inflammatory bowel disease, Behcet's syndrome, gout, cancer, viral infections, bacterial infections, organ transplant conditions and skin transplant conditions.

24. The method of Claim 23 that comprises administering to the subject an amount of a parent compound according to formula (II):



that provides the subject a therapeutically or prophylactically effective amount of the compound of Claim 1.